AMIKACIN (Arikayce Liposomal®)

Clinical Indication

For the treatment of non-tuberculous mycobacterial pulmonary disease caused by Mycobacterium Avium Complex (MAC) adults and post pubescent children)

Date of classification

December 2022


Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.